Abstract
Primary inherited hyperphenylalaninaemia is probably best defined as a ratio of blood phenylalanine to tyrosine persistently greater than 3 (approximate normal ranges for blood concentrations: phenylalanine 35–120 μmol/1; tyrosine 40–130 μmol/1). Hyperphenylalaninaemia arises due to a block in the conversion of phenylalanine into tyrosine due to a defect in either the enzyme phenylalanine hydroxylase (98% of subjects) or in the metabolism of the cofactor tetrahydrobiopterin (BH4). Increases production of phenylketones [hence phenylketonuria (PKU)] occurs in parallel with the rise in phenylalanine level. BH4 is also the cofactor required for conversion of tyrosine into L-dopa, of tryptophan into 5-hydroxy-tryptophan and of arginine into nitric oxide (NO). In Caucasians, persistent hyperphenylalaninaemia occurs in between t in 4000 and t in 40,000 newborns. Although there is a considerable variation in genotype and phenotype, the gteat majority of affected subjects are at risk of intellectual and neurological impairments and handicaps, which can be prevented by introduction of strictly controlled treatment within a few weeks of birth (a phenylalanine-restricted diet with the addition of drug therapy for subjects with cofactor defects). Neonatal screening detects all but a few affected subjects. Definitive diagnosis relies on the measurement of blood phenylalanine and tyrosine and the exclusion of cofactor defects by measurement of pterins and dihydropteridine reductase (DHPR). The foetus, like the newborn infant, is at risk of damage proportionate to the degree of hyperphenylalaninaemia. The offspring of affected and untreated mothers present with low birth weight, reduced longitudinal pre- and postnatal growth, microcephaly, facial dysmorphism and a range of other congenital anomalies, notably in the heart and large vessels. It is of great importance that potential mothers with hyperphenylalaninaemia receive well-controlled treatment from before conception to the end of pregnancy. Within one generation, failure to achieve proper management for maternal PKU will result in loss of the benefits of neonatal screening.
Keywords
- Phenylalanine Hydroxylase
- Phenylalanine Level
- Phenylalanine Concentration
- Blood Phenylalanine
- Dihydropteridine Reductase
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kaufman S (1987) Tetrahydrobiopterin and hydroxylation systems in health and disease. In: Lovenberg W, Levine RA (eds) Unconjugated pteridines in neurobiology: basic and clinical aspects. Taylor and Francis, London, pp 1–28
Medical Research Council Working Party on Phenylketonuria (1993) Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Br Med J 306: 115–119
Pardridge WM (1998) Blood brain barrier carrier mediated transport and brain metabolism of amino acids. Neurochem Res 23:635–644
Bannon MJ, Bunney EB, Roth RH (1981) Mesocortical dopamine neurons: rapid transmitter turnover compared to other brain catecholamine systems. Brain Res 218: 376–382
Tillotson SL, Costello PM, Smith I (1995) No reduction in birth weight in phenylketonuria. Eur J Paediatr 154: 847–849
Smith I, Cook B, Beasley M (1991) Review of neonatal screening programme for phenylketonuria. Br Med J 303: 333–335
Report of Medical Research Council Working Party on Phenylketonuria (1993) Recommendations on the dietary management of phenylketonuria. Arch Dis Child 68: 426–427
Guldberg P, Rey F, Zschocke J et al. (1998) A European multicentre study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a system of genotype-based prediction of metabolic phenotype. Am J Hum Genet 63: 71–79
Burgard P, Bremer HJ, Buhrdel P et al. (1999) Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Paediatr 158: 46–54
Prince AP, McMurray HP, Buist NR (1997) Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials. J Inherit Metab Dis 20: 486–498
MacDonald A, Rylance GW, Asplin D, Hall SK, Booth IW (1998) Does a single plasma phenylalanine predict quality of control in phenylketonuria? Arch Dis Child 78: 122–126
Azen C, Koch R, Friedman E, Wenz E, Fishier K (1996) Summary of findings from the United States- Collaborative Study of Children treated for Phenylketonuria. Eur J Paediatr 155 [Suppl 11:529–532
Paul AA, Southgate DAT (1992) McCance and Widdowson’s. The composition of foods. Royal Society of Chemistry and Ministry of Agriculture, Fisheries and Foods, Cambridge
Riva E, Agostoni C, Biasucci G et al. (1996) Early breast feeding is linked to higher intelligent quotient scores in dietary treated phenylketonuric children. Acta Paediatr 85: 56–58
Galli C, Agostini C, Mosconi C, Riva E, Salari P, Giovannini H (1991) Reduced plasma and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. J Pediatr 1191: 562–567
Hanley WB, Feigenbaum AS, Clarke JT, Schoonheyt WE, Austin VJ (1996) Vitamin B12 deficiency in adolescents and young adults with phenylketonuria. Eur J Paediatr 155 [Suppl]: S145–147
Lee P, Smith I, Piesowicz A, Brenton DP (1999) Spastic paresis after anaesthesia. Lancet 353: 554
Diamond A, Herzberg C (1996) Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. Brain 19: 523–538
Smith I (1985) The hyperphenylalaninaemias. In: Lloyd JK, Scriver CR (eds) Genetic and metabolic disease. Butterworth, London, pp 166–210
McDonnell GV, Esmond TF, Hadden DR, Morrow JI (1998) A neurological evaluation of adult phenylketonuria in Northern Ireland. Eur Neurol 39:38–43
Lenke RL, Levy HL (1980) Maternal phenylketonuria and hyperphenylalaninaemia. N Engl J Med 303: 1202–1208
Smith I, Glossop J, Beasley M (1990) Fetal damage due to maternal phenylketonuria: effects of dietary treatment and maternal phenylalanine concentrations around the time of conception. J Inherit Metab Dis 13: 651–657
Levy HL, Waisbren SE, Lobbregt D et al. (1994) Maternal mild hyperphenylalaninaemia: an international survey of offspring outcome. Lancet 344: 1589–1594
Soltesz G, Harris D, Mackenzie IZ, Aynsley-Green A (1985) The metabolic and endocrine milieu of the human fetus and mother at 18–21 weeks of gestation. 1. Plasma amino acid concentrations. Pediatr Res 19: 91–92
Brenton DP, Lilburn M (1996) Maternal phenylketonuria. A study from the United Kingdon. Eur Paediatr 155 [Suppl1]: 5177–18o
Rouse B, Azen C, Koch R et al. (1997) Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations and early neurological sequelae. Am J Med Genet 69: 89–95
Hanley WB, Koch R, Levy HL et al. (1996) The North American Maternal Phenylketonuria Collaborative Study, developmental assessment of the offspring: preliminary report. Eur J Paediatr 155 [Suppl 1]: S169–172
Blau N, Thony B, Heizmann CW, Dhondt J-L (1993) Tetrahydrobiopterin deficiency: from phenotype to genotype. Pteridines 4: 1–10
Bandemann O, Valente EM, Holmans P et al. (1998) Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol 44: 649–656
Thony B, Neuheiser F, Kierat L et al. (1998) Mutations in the pterin 4 alphacarbinolamine dehydratase ( PCBD) gene cause a benign form of hyperphenylalaninaemia. Hum Genet 103: 162–167
Blau N, Duran M, Blaskovics ME (eds) (1996) Physician’s guide to the laboratory diagnosis of metabolic diseases. Chapman and Hall Medical, London
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Smith, I., Lee, P. (2000). The Hyperphenylalaninaemias. In: Fernandes, J., Saudubray, JM., Van den Berghe, G. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04285-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-662-04285-4_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-04287-8
Online ISBN: 978-3-662-04285-4
eBook Packages: Springer Book Archive